Date of this Version
International Journal of the Economics of Business
The market-based US health care system relies on pharmacy benefit managers (PBMs) to control pharmaceutical costs, in contrast to most other countries that regulate drug prices and access. Optimal strucuturing and regulation of PBM contracts poses significant agency challenges for private and public payers. However, recent reporting requirements for PBMs may be counterproductive and reflect the interests of competitors rather than customers.
This is an Accepted Manuscript of an article published by Taylor & Francis in the International Journal of the Economics of Business on June 26, 2015, available online: http://dx.doi.org/10.1080/13571516.2015.1045741
pharmaceuticals, pharmacy benefit management, insurance, transparency, regulation
Danzon, P. M. (2015). Pharmacy Benefit Management: Are Reporting Requirements Pro- or Anticompetitive?. International Journal of the Economics of Business, 22 (2), 245-261. http://dx.doi.org/10.1080/13571516.2015.1045741
American Politics Commons, Business Administration, Management, and Operations Commons, Business Law, Public Responsibility, and Ethics Commons, Health and Medical Administration Commons, Health Policy Commons, Insurance Commons, Organizational Behavior and Theory Commons, Pharmacoeconomics and Pharmaceutical Economics Commons, Pharmacy Administration, Policy and Regulation Commons
Date Posted: 26 June 2018
This document has been peer reviewed.